Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.24 per share a year ago.
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript
Tenaya Therapeutics, Inc. ( TNYA ) Shareholder/Analyst Call November 10, 2025 8:00 AM EST Company Participants Michelle Corral - Vice President of Investor Relationship & Corporate Communications Faraz Ali - CEO, Interim Principal Financial Officer & Director Whittemore G. Tingley - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Michael Ulz - Morgan Stanley, Research Division Sara Nik - H.C.
Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Tenaya Therapeutics, Inc. (NASDAQ:TNYA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Faraz Ali - CEO, Interim Principal Financial Officer & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst Okay. Great. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Tenaya Therapeutics price target lowered to $6 from $8 at Leerink
Leerink lowered the firm's price target on Tenaya Therapeutics to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy following program updates in October. The firm notes that while evidence of expression was present, clinical benefit is yet to be determined. Updated Cohort 1 data are expected in the first half of 2025, while initial Cohort 2 and MyClimb natural history data are expected in 2025.
